10th Circ. Tosses Sanofi's EpiPen Antitrust Suit Against Mylan
A Tenth Circuit panel ruled Friday that Sanofi-Aventis US LLC cannot pursue allegations that Mylan illegally blocked a potential competitor to its emergency allergy treatment EpiPen, finding there's not enough evidence...To view the full article, register now.
Already a subscriber? Click here to view full article